A phase II study of telisotuzumab vedotin in patients with c-MET-positive stage IV or recurrent squamous cell lung cancer (LUNG-MAP sub-study S1400K, NCT03574753) - Waqar, S N; Redman, M W; Arnold, S M (Clin Lung Cancer, 2021)